| Literature DB >> 21507220 |
Marilisa Novacco1, Felicitas S Boretti, Godelind A Wolf-Jäckel, Barbara Riond, Marina L Meli, Barbara Willi, Hans Lutz, Regina Hofmann-Lehmann.
Abstract
"Candidatus Mycoplasma turicensis" infects felids. The pathogenesis of "Candidatus M. turicensis" chronic infection is poorly understood. The goals of the present study were to (1) induce reactivation of the infection in chronic carrier cats by attempted immunosuppression, (2) identify potential tissue sequestration using real-time TaqMan® PCR and (3) monitor the humoral immune response by DnaK enzyme-linked immunosorbent assay (ELISA). Ten specified pathogen-free cats that had ostensibly recovered from experimental "Candidatus M. turicensis" infection were used: five cats (group 1) received high dose methylprednisolone (attempted immunosuppression), while five cats served as untreated controls (group 2). Besides weekly blood samples, tissue samples were collected from bone marrow, kidney, liver and salivary glands at selected time points. The cats in group 1 had significantly lower lymphocyte counts and higher blood glucose levels after methylprednisolone administration than the controls. After methylprednisolone administration one blood and three tissue samples from cats in group 1 tested PCR-positive; before the administration, only one sample was positive. All other samples tested PCR-negative. All cats stayed seropositive; the antibody levels of the cats in group 1 showed a significant transient decrease after methylprednisolone administration. This is the first study to report the presence of "Candidatus M. turicensis" in tissues of chronically infected cats and the persistence of anti-feline hemoplasma antibodies in the absence of detectable bacteremia. Methylprednisolone administration did not lead to a significant reactivation of the infection. Our results enhance the knowledge of "Candidatus M. turicensis" infection pathogenesis and are clinically relevant to the prognosis of hemoplasma-infected cats.Entities:
Mesh:
Year: 2011 PMID: 21507220 PMCID: PMC3090992 DOI: 10.1186/1297-9716-42-59
Source DB: PubMed Journal: Vet Res ISSN: 0928-4249 Impact factor: 3.683
CMt TaqMan® real-time PCR results of blood and tissue samples collected prior to and after the methylprednisolone administrations
| Group | Cat | Before MPAa | 1 week after end MPA | 4 weeks after end MPA |
|---|---|---|---|---|
| 1 | A2 | -b | - | - |
| R2 | +c salivary gland (264d) | + salivary gland (10 250 d) | - | |
| S1 | - | + blood (800e) | - | |
| T1 | - | + liver (838 d) | - | |
| X4 | - | - | - | |
| 2 | A1 | - | - | - |
| R1 | - | - | - | |
| S2 | - | - | - | |
| T2 | - | - | - | |
| X5 | - | - | - |
a MPA = methylprednisolone administrations; b - = all samples tested PCR-negative; c + = at least one PCR-positive result; the positive tissues are listed; d tissue loads: copies/106 cells; e blood loads: copies/mL of blood.
Figure 1Lymphocyte counts (A) and blood glucose levels (B) of cats in groups 1 and 2. Values are depicted as mean +/- standard deviation. Black arrows = methylprednisolone administration. Cats in group 1 received the methylprednisolone administrations; cats in group 2 served as untreated control animals. A) Cats in group 1 had significantly lower lymphocyte counts than cats in group 2 (pMWU < 0.05) starting after the first methylprednisolone administration until day 70. B) Cats in group 1 had significantly higher blood glucose levels than cats in group 2 (pMWU < 0.05) starting after the first methylprednisolone administration at all collection time points with the exceptions of days 2, 11, and 36.
Figure 2Antibody levels to DnaK depicted as ELISA signal-to-noise ratio. A) Cats in group 1; methylprednisolone administration (black arrows); B) cats in the untreated control group 2.